肿瘤细胞治疗研究
英文原题：Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management.
原发性皮肤T细胞淋巴瘤（CTCLs）中，除蕈样肉芽肿（MF）和Sézary综合征（SS）外，还包括一组异质性非霍奇金淋巴瘤，其临床病程、预后和管理方法各不相同。
除蕈样肉芽肿（MF）和Sézary综合征（SS）以外的原发性皮肤T细胞淋巴瘤（CTCLs）包括一组异质性非霍奇金淋巴瘤，其临床病程、预后和管理方法各不相同。鉴于CTCL亚型与其他具有皮肤表现的T细胞淋巴瘤之间存在形态学和组织学重叠，在开始治疗前，必须进行全面的评估，包括临床病理相关性分析并排除系统性受累。分期和治疗建议因亚型、临床行为和治疗反应而异。一般来说，对于推荐进行分期的亚型，使用Ann Arbor分期或针对非MF/SS的CTCL特异性肿瘤、淋巴结、转移分期。对于许多亚型，迄今为止尚无标准治疗。可用的推荐治疗方案范围广泛，从无需积极干预或仅进行最小干预的皮肤导向治疗，到包括多药化疗并考虑造血干细胞移植的积极系统性治疗。新兴的靶向治疗，如brentuximab——一种靶向CD30的嵌合抗体——在改变非MF/SS CTCLs的疾病进程方面显示出前景。
Primary cutaneous T-cell lymphomas (CTCLs) other than mycosis fungoides (MF) and Sézary syndrome (SS) encompass a heterogenous group of non-Hodgkin lymphomas with variable clinical courses, prognoses, and management approaches. Given the morphologic and histologic overlap among the CTCL subtypes and other T-cell lymphomas with cutaneous manifestations, thorough evaluation with clinicopathologic correlation and exclusion of systemic involvement are essential prior to initiating therapy. Staging and treatment recommendations vary, depending on the subtype, clinical behavior, and treatment response. Generally, for subtypes in which staging is recommended, Ann Arbor or tumor, node, metastasis staging specific to CTCL other than MF or SS are used. For many subtypes, there is no standard treatment to date. Available recommended treatments range widely, from no active or minimal intervention with skin-directed therapy to aggressive systemic therapies that include multi-agent chemotherapy with consideration for hematopoietic stem cell transplant. Emerging targeted therapies, such as brentuximab, a chimeric antibody targeting CD30, show promise in altering the disease course of non-MF/SS CTCLs.
MEMBER ACCOUNT
登录成功会直接打开下一页。
